Bevacizumab as Adjuvant Therapy in the Treatment of Keloid: A Randomized Clinical Trial

Table 3

Clinical outcomes during the study periods.

Outcomes	Time points	TriamHEXAL		TriamHEXAL + Avastin		Changes
		Mean	SD	Mean	SD	Mean 95% CI
VAS score	Month 1	5.68	2.11	6.47	2.35	0.79 (−2.30, 0.72)	0.297
	Month 3	5.95	2.30	7.24	2.49	1.29 (−2.91, 0.33)	0.116
	Month 3-month 1	0.26	1.19	0.76	0.83	0.50 (−0.20, 1.21)	0.158
		0.35		<0.001
Height (mm)	Baseline	2.84	1.25	3.58	1.57	0.74 (−1.67, 0.20)	0.119
	Month 1	1.55	0.96	1.68	1.44	0.12 (−0.94, 0.69)	0.760
	Month 1-baseline	1.29	0.85	1.74	1.03	0.45 (−1.09, 0.19)	0.166
	Month 3	1.37	1.00	1.21	1.53	0.16 (−0.70, 1.03)	0.705
	Month 3-baseline	1.47	0.79	2.21	1.06	0.73 (−1.36, −0.10)	0.024
		<0.001		<0.001

The significance of all values is <0.05.